194 related articles for article (PubMed ID: 31195902)
1. The levonorgestrel-releasing intrauterine device induces endometrial decidualisation in women on tamoxifen.
Philip S; Taylor AH; Konje JC; Habiba M
J Obstet Gynaecol; 2019 Nov; 39(8):1117-1122. PubMed ID: 31195902
[TBL] [Abstract][Full Text] [Related]
2. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Chin J; Konje JC; Hickey M
Cochrane Database Syst Rev; 2009 Oct; (4):CD007245. PubMed ID: 19821400
[TBL] [Abstract][Full Text] [Related]
3. mRNA expression of insulin-like growth factor-I (IGF-I) is suppressed and those of IGF-II and IGF-binding protein-1 are constantly expressed in the endometrium during use of an intrauterine levonorgestrel system.
Rutanen EM; Salmi A; Nyman T
Mol Hum Reprod; 1997 Sep; 3(9):749-54. PubMed ID: 9357999
[TBL] [Abstract][Full Text] [Related]
4. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Dominick S; Hickey M; Chin J; Su HI
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007245. PubMed ID: 26649916
[TBL] [Abstract][Full Text] [Related]
5. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Romero SA; Young K; Hickey M; Su HI
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD007245. PubMed ID: 33348436
[TBL] [Abstract][Full Text] [Related]
6. Morphological and functional features of endometrial decidualization following long-term intrauterine levonorgestrel delivery.
Critchley HO; Wang H; Jones RL; Kelly RW; Drudy TA; Gebbie AE; Buckley CH; McNeilly AS; Glasier AF
Hum Reprod; 1998 May; 13(5):1218-24. PubMed ID: 9647550
[TBL] [Abstract][Full Text] [Related]
7. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system.
Critchley HO; Wang H; Kelly RW; Gebbie AE; Glasier AF
Hum Reprod; 1998 May; 13(5):1210-7. PubMed ID: 9647549
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients: a meta-analysis.
Fu Y; Zhuang Z
Int J Clin Exp Pathol; 2014; 7(10):6419-29. PubMed ID: 25400720
[TBL] [Abstract][Full Text] [Related]
9. Continuous combined parenteral estrogen substitution and intrauterine progestogen delivery: the ideal HST combination?
Wildemeersch D; Janssens D; Weyers S
Maturitas; 2005 Jun; 51(2):207-14. PubMed ID: 15917162
[TBL] [Abstract][Full Text] [Related]
10. Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system long-term follow-up of a randomised control trial.
Gardner FJ; Konje JC; Bell SC; Abrams KR; Brown LJ; Taylor DJ; Habiba M
Gynecol Oncol; 2009 Sep; 114(3):452-6. PubMed ID: 19576623
[TBL] [Abstract][Full Text] [Related]
11. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy.
Varila E; Wahlström T; Rauramo I
Fertil Steril; 2001 Nov; 76(5):969-73. PubMed ID: 11704119
[TBL] [Abstract][Full Text] [Related]
12. The effect of intrauterine and oral levonorgestrel administration on serum concentrations of sex hormone-binding globulin, insulin and insulin-like growth factor binding protein-1.
Pakarinen P; Lähteenmäki P; Rutanen EM
Acta Obstet Gynecol Scand; 1999 May; 78(5):423-8. PubMed ID: 10326889
[TBL] [Abstract][Full Text] [Related]
13. Levonorgestrel intrauterine system in adjuvant tamoxifen treatment: balance of breast risks and endometrial benefits--systematic review of literature.
Gizzo S; Di Gangi S; Bertocco A; Noventa M; Fagherazzi S; Ancona E; Saccardi C; Patrelli TS; D'Antona D; Nardelli GB
Reprod Sci; 2014 Apr; 21(4):423-31. PubMed ID: 24060633
[TBL] [Abstract][Full Text] [Related]
14. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
Lethaby A; Hussain M; Rishworth JR; Rees MC
Cochrane Database Syst Rev; 2015 Apr; (4):CD002126. PubMed ID: 25924648
[TBL] [Abstract][Full Text] [Related]
15. Insulin-like growth factor-binding protein-1: a biochemical marker of endometrial response to progestin during hormone replacement therapy.
Suvanto-Luukkonen E; Sundström H; Penttinen J; Kauppila A; Rutanen EM
Maturitas; 1995 Nov; 22(3):255-62. PubMed ID: 8746884
[TBL] [Abstract][Full Text] [Related]
16. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
Sturridge F; Guillebaud J
Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factors and insulin-like growth factor binding proteins in the endometrium. Effect of intrauterine levonorgestrel delivery.
Rutanen EM
Hum Reprod; 2000 Aug; 15 Suppl 3():173-81. PubMed ID: 11041233
[TBL] [Abstract][Full Text] [Related]
18. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial.
Gardner FJ; Konje JC; Abrams KR; Brown LJ; Khanna S; Al-Azzawi F; Bell SC; Taylor DJ
Lancet; 2000 Nov; 356(9243):1711-7. PubMed ID: 11095258
[TBL] [Abstract][Full Text] [Related]
19. Intrauterine levonorgestrel delivered by a frameless system, combined with systemic estrogen: acceptability and endometrial safety after 3 years of use in peri- and postmenopausal women.
Wildemeersch D; Janssens D; Schacht E; Pylyser K; de Wever N
Gynecol Endocrinol; 2005 Jun; 20(6):336-42. PubMed ID: 16019384
[TBL] [Abstract][Full Text] [Related]
20. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
Lethaby AE; Cooke I; Rees M
Cochrane Database Syst Rev; 2005 Oct; (4):CD002126. PubMed ID: 16235297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]